Maurice Zauderer - Apr 1, 2022 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
President and CEO, Director
Signature
/s/ Scott E. Royer, Attorney-in-Fact for Maurice Zauderer
Stock symbol
VCNX
Transactions as of
Apr 1, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:34 PM
Previous filing
Jan 31, 2022
Next filing
Nov 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VCNX Common Stock 178K Apr 1, 2022 Direct
holding VCNX Common Stock 213K Apr 1, 2022 By Jeremy C. Zauderer Trust F1
holding VCNX Common Stock 212K Apr 1, 2022 By Jordan M. Zauderer Trust F1
holding VCNX Common Stock 2.9M Apr 1, 2022 By Vaccinex (Rochester), L.L.C. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCNX Stock Option (Right to Buy) Award $0 +28K $0.00 28K Apr 1, 2022 Common Stock 28K $1.29 Direct F7
holding VCNX Stock Option (Right to Buy) 2.59K Apr 1, 2022 Common Stock 2.59K $14.90 Direct F3
holding VCNX Stock Option (Right to Buy) 2.59K Apr 1, 2022 Common Stock 2.59K $14.90 Direct F3
holding VCNX Stock Option (Right to Buy) 3.33K Apr 1, 2022 Common Stock 3.33K $7.10 Direct F3
holding VCNX Stock Option (Right to Buy) 20K Apr 1, 2022 Common Stock 20K $4.29 Direct F4
holding VCNX Stock Option (Right to Buy) 28.4K Apr 1, 2022 Common Stock 28.4K $6.68 Direct F5
holding VCNX Stock Option (Right to Buy) 14K Apr 1, 2022 Common Stock 14K $2.93 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F2 Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3 Exercisable in full as of the date of this report.
F4 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
F5 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
F6 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
F7 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.